The human side of leadership: Inspirational leadership effects on follower characteristics and happiness at work (HAW)

Leadership has received significant attention over the past years. Now is the time to refine how leaders impact on followers and their attitudes. This study examines how inspirational leaders influence follower characteristics (FC), and in turn, their happiness at work. In this study, the mediating effect of follower characteristics in the relationship between inspirational leadership and happiness at work was specifically examined. Data was gathered from 389 frontline banking employees working in Italian and Spanish banks. A confirmatory factor analysis revealed a positive partial mediating role of follower characteristics in the relationship between inspirational leadership and happiness at work. Results showed that inspirational leadership exerts a more positive influence on followers' happiness at work when follower characteristics are more positive. Our discussion highlights the importance of understanding the role of the follower characteristics that are involved in the effectiveness of inspirational leadership

Does a CDO enhance Company Inventiveness? An Empirical Study on new Managerial Positions and Innovation

Digital technology has advanced rapidly in the last few years. Consequently, companies need to transform their business and operations models to keep up with these advances, placing digital transformation (DT) as a top priority. Beyond the possible effects of using more digital technologies, is more innovation. One way in which companies can stimulate DT is by creating a new top-management position, the Chief Digital Officer (CDO). Although evidence has been found about the relationship between digital technologies and innovation, the role of the CDO as an enabler has been less studied. We use difference-in-difference estimators to measure this effect, using a unique dataset with 39 companies that appointed a CDO and 39 comparable companies that did not as a control group. We find a significant increase in patent filings as early as the first year CDO’s appointment. We find evidence that a managerial role can have an effect on innovation

Cell surface immobilization of GABAARs in cerebellar granule cells depends on the M3/M4 cytoplasmatic loop of the alpha 1 subunit

Gamma-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the vertebrate brain. The localization of GABA receptors type A (GABAARs) at strategically located domains of the neuronal membrane is of vital importance for fast inhibitory synapse transmission efficacy. We have shown before that the lateral mobility of GABAARs depends on subunit composition of the complex. To study the lateral mobility of GABAARs in living, cultured neurons, we transfected cerebellar granule cells with either the complete 1 GABAAR subunit or with a truncation of the 1 subunit that lacks the major intracellular loop (M3/M4). We examined the location and lateral mobility of receptors containing both versions of the 1 subunit in living neurons. From fluorescence recovery after photobleaching experiments we present novel evidences that the intracellular M3/M4 loop of the 1 subunit restricts the lateral mobility of GABAARs when expressed in neurons. In addition, our immunocytochemical studies suggested that receptors containing the truncated subunit seem to be unable to reach synaptic localizations. Here we show for the first time that the 1 intracellular loop (M3/M4) domain has a relevant role in controlling the lateral mobility of GABAARs in neurons, and we believe that this is a novel and important contribution in neurobiology of GABAA receptors

Glycosylate Derivatives of Mithramycin, Method of Preparation and Uses Thereof

The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget\u27s disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson\u27s, Alzheimer\u27s, Huntington\u27s)